Control Bionics Share Price and Company Fundamentals
Last traded: Last Friday at 5:54 AM
Control Bionics Limited engages in the research, development, commercialization, and sale of assistive communications technology systems that allows user with speech and movement disabilities in Australia and North America. It offers NeuroNode Trilogy, a wearable device solution for those living with paralysis and loss of speech; NeuroNode3, a wearable EMG control device; and Control Bionics CCS that allow users to communicate with friends and family, send and receive emails and text messages, browse the web, watch videos and movies, read the news, play games, control their home environmental control systems, and others. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Surrey Hills, Australia.
|Primary activities||Technology company that designs, manufactures and sells augmentative and alternative communication technology that allows users to operate and communicate via computer using their thoughts and neural signals|
|Industry / Sector||Medical Devices / Healthcare|
|Mailing address||171 Union Road Suite G.03 Surrey Hills VIC 3127 Australia|
|Phone / Fax||61 3 9897 3576 /|
|Share registry||AUTOMIC REGISTRY SERVICES|
Control Bionics does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Control Bionics.
|Mr. Robert William Wong||CEO & Board Member|
|Mr. Peter Shann Ford||Founder, Exec. Director & Director of Innovation|
|Mr. Neale Java||Chief Financial Officer|
|Mr. James Schorey||Chief Technology Officer|
|Ms. Meagan Koeneman||Sales Director|
|Mr. Brett Crowley B.Com., BCom, C.A., CA, DipLaw||Company Sec.||63|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Control Bionics is 50.96M and its enterprise value is 50.94M. The enterprise value to revenue ratio of CBL is 12.46.
Companies similar to Control Bionics (CBL)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Control Bionics (ASX:CBL) Frequently Asked Questions
1. What is Control Bionics's Stock Symbol?
Control Bionics trades on ASX under the ticker symbol "CBL".
2. What is Control Bionics's stock price today?
One share of CBL stock can currently be purchased for approximately $0.61.
3. How can I contact Control Bionics?
Control Bionics's mailing address is 171 Union Road Suite G.03 Surrey Hills VIC 3127 Australia. The company can be reached via phone at 61 3 9897 3576.
4. What is Control Bionics's official website?
The official website of Control Bionics is http://www.controlbionics.com.
5. Which share registry manages Control Bionics's stock?
Control Bionics's stock is managed by AUTOMIC REGISTRY SERVICES.